It would be interesting to know the target market for MBI 853NL. I believe MBI 853NL has the potential to replace Vancomycin as the drug to treat S. Aureus (SA). Vancomicin is a restricted drug with annual sales of US$250 million (1998). MBI 853NL wont have the same restrictions as placed on Vancomycin which should result in greater sales.
The death rate associated with a staph infection is incredibly high.
>>Out of these 260,000 infections, 60,000 to 80,000 people die each year. That comes down to 200 people each day (or 8 people every hour). By the time you have finished reading this web page, one person will have died of a Staph infection.<<
student.biology.arizona.edu
The market for hospital-acquired MRSA is thought to be $20 million annually.
>>Vancomycin alone generates about $250 million in sales worldwide. MRSA, which accounts for 108,000 of 270,000 cases of hospital-acquired Staphylococcus aureus (SA) infections in the U.S., could produce sales of more than $20 million, according to estimates by Tarrytown, N.Y.-based AMBI Inc., a biotechnology firm developing two promising strategies against drug-resistant infections.<<
the-scientist.library.upenn.edu
Any thoughts? |
